Stifel analyst Alex Schwartz noted that Esperion relayed at a conference last week that the company has received blinded adverse event data from their ongoing Phase 3 program for bempedoic acid. Based on the company's comments regarding the blinded data, Schwartz is increasingly positive on bempedoic acid's safety profile over 52 weeks, he tells investors. The analyst, who increased his estimated bempedoic acid WAC price and raised his view of the probability of success in the Phase 3 bempedoic acid monotherapy trials to 75%, increased his price target on Esperion shares to $105 from $70 and keeps a Buy rating on the name.